Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
24 avr. 2023 16h01 HE
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
18 avr. 2023 16h01 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Organovo Announces FXR Program
21 mars 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Stoma/Ostomy Care Global Market to Reach $5.1 Billion by 2030: Rising Incidence of Colorectal Cancer, Bladder Cancer and IBD and Drives the Need for Ostomy Care Products
02 mars 2023 11h43 HE
|
Research and Markets
Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Stoma/Ostomy...
Stoma/Ostomy Care Global Market 2022: Sector to Reach $4.1 Billion by 2027 at a CAGR of 4.22%
16 févr. 2023 04h23 HE
|
Research and Markets
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Global Gastrointestinal Partnering Report and Directory 2022: Trends by Year, Deal Type, Stage of Development, Technology Type and Therapeutic Indication
02 déc. 2022 08h09 HE
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The...
Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
08 nov. 2022 06h13 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
02 nov. 2022 08h00 HE
|
Morphic Therapeutic
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter ...
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
25 oct. 2022 16h05 HE
|
Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
24 oct. 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...